Panel
Advancing Precision Oncology: Prevention, Early Detection, & Treatment | Middle East & Africa Summit
- Precision oncology transformation: Shift from "one-size-fits-all" chemotherapy to tumor-specific, biomarker-driven treatments has increased advanced lung cancer survival rates from 10–15% to 40–45%, with early detection achieving up to 85% survival in select systems.
- Metabolic-Cancer intersection: Obesity is linked to 13 specific cancer types, while cardiovascular disease and diabetes increase cancer risk via shared mechanisms of inflammation and elevated IGF-1 signaling; conversely, treating cardiometabolic risks during cancer therapy improves treatment efficacy.
- AI in drug development: Artificial intelligence is being utilized to analyze 3.2 billion DNA permutations and epigenomic signatures to match therapies to mutations and accelerate drug discovery, potentially reducing the traditional 36-month clinical trial timeline to 18 months through automated lab testing.
- Robotic surgery evolution: Current robotic systems augment human surgeons by eliminating tremors, improving visual magnification, and reducing blood loss and infection rates, with future goals including autonomous sub-routines and remote surgery capabilities demonstrated via a procedure from Abu Dhabi to Afghanistan.
- Abu Dhabi genomic initiative: The UAE aims to integrate Emirati Genome Project data with metabolic risk scores to create a unique "global risk" profile for individuals, aligning government incentives to pay for preventive interventions rather than reactive treatment.
- Liquid biopsy adoption: Guardant Health's Shield multi-cancer screening test is being deployed via public-private partnerships in Abu Dhabi and Japan to address the <10% colorectal cancer screening rates in the GCC, targeting high mortality cancers for early detection.
- GLP-1 repurposing: GLP-1 agonists are being studied for cancer prevention due to their impact on the root metabolic pathways (inflammation and glucose-insulin signaling) shared between metabolic disease and cancer, with regulators in Abu Dhabi and the US approving them for weight loss to support population health.
- mRNA technology outlook: Beyond vaccines, mRNA technology is expanding into personalized "n-of-one" cancer vaccines and immunotherapies for various chronic diseases, moving from a stigmatized topic to a frontier of healthcare.
- Screening disparity: Breast cancer is diagnosed in 45% of cases under age 50 in the UAE compared to 8% in North America, attributed to high regional rates of diabetes, obesity (70% of males over 30 are overweight), and environmental exposures.
- 2050 Cancer Outlook: Consensus among panelists is that cancer will likely transition from a fatal acute disease to a manageable chronic condition by 2050 through a combination of aging-related cell mutations management, early screening, and prevention strategies.
- Advocacy role: Friends of Cancer Patients has screened over 1,000 individuals in 2024, providing over 9 million AED in financial support, and emphasizes the necessity of integrating patient voices into policy design to address stigma and navigation barriers.